Our Consulting Services operate as an extension of your team to help design and execute an efficacious preclinical development program. Our exploratory preclinical safety evaluation approach identifies dose/exposure relationships for tolerability, as well as identification of organs and/or systems susceptible to adverse pharmacology or toxicology. The goal is to discover potential flaws in novel pharmaceutical compounds that limit their development prior to the investment of significant time and money.

Additionally, Seventh Wave’s commitment to scientific continuity serves as a constant source of consultative support. By working with the same pharmcokineticist, toxicologist, and pathologist throughout the development continuum, clients receive expertise and insights from those intimately involved in the process—throughout the duration of the process.